| INTRODUCTION
Benign prostatic hyperplasia (BPH) is one of the most frequent medical conditions in aging men and one of the most common chronic diseases among the male population. BPH is progressive, as it evolves from asymptomatic tissue alterations to clinical disease with lower urinary tract symptoms (LUTS). These symptoms have an important effect on the quality of life and can lead to acute urinary retention if untreated. 1 Hence improvement in the prevention and clinical treatment of this condition would be beneficial.
Although the pathogenesis and etiology of BPH are not entirely understood, hormonal dysregulation seems to play an essential role as a shift in prostatic androgen metabolism occurs with aging. This causes abnormal accumulation of dihydrotestosterone, resulting in prostate enlargement. 2 Also local growth factors and complex inflammation appear to have an impact on BPH. BPH is often accompanied by metabolic syndrome, a condition characterized by systemic inflammation. 2 Thus, use of non-steroidal anti-inflammatory drugs (NSAIDs) may affect BPH by reducing inflammation. NSAIDs are prescribed for analgesia in various common conditions with pain and inflammation.
Both BPH and NSAID usage are common in older men which highlights the importance of understanding their interrelationship.
Evidence regarding the role of inflammation in BPH has been accumulating and inflammatory pathways seem to play significant role
The Prostate. 2017;77:1029-1035. wileyonlinelibrary.com/journal/pros in different phases of BPH. This has been indicated by histological studies reporting intraprostatic inflammation in 43-98% of BPH tissue samples. 3, 4 High C-reactive protein concentration has also been associated with an increased BPH risk. 5 T-cell derived cytokines may contribute and enhance prostatic growth 6 as various interleukins increase the expression of cyclooxygenase 2 (COX-2), which is upregulated on macrophages and epithelial cells in BPH. 7 Thus inhibition of inflammatory pathways by NSAIDs could decrease and inhibit the development of BPH. Such an effect has been reported in vitro. 8 The amount of epidemiological research on this subject is scarce and results somewhat conflicting. One of the few studies reported a weak positive association between regular NSAID use and prevalent BPH/LUTS, 9 whereas another study found a strong inverse association between daily NSAID use and incident BPH/LUTS. 10 Tampere and Helsinki areas in 1996-1999. These men were randomized either to be invited to screening with PSA test at 4-year intervals (screening arm) or to the control arm with no intervention, both groups followed via national health-care registries.
In total, 32 000 men were randomized to the screening arm. Men over 71 years old were no longer invited for re-screening (men 67 years old at entry were screened twice, whereas those aged 55, 59, or 63 years three times). The follow-up continued until the end of 2013. Both registries cover all hospitals (whether public or private) and the entire population of Finland.
| Statistical methods
Risk of BPH was compared by overall NSAID usage, previous or current usage and by length of usage as compared to non-users. For comparison, BPH risk was separately analyzed by aspirin and coxib usage.
The analysis was performed using Cox regression to calculate hazard ratios (HRs) and their 95% confidence intervals (95% CIs) for the three separate BPH outcomes defined earlier. Analysis was adjusted for age and use of other medications (statins, antidiabetic drugs, and antihypertensive drugs).
NSAID usage was analyzed as a time-dependent variable, with usage status, as well as cumulative length of usage were updated for each year of follow-up based on yearly NSAID purchases. We performed separate analysis for NSAID ever-users, and an analysis of current users (men still using NSAIDs on a given follow-up year) and previous users (usage on previous years, but not on the observation year).
Users were stratified into quartiles according to the total cumulative number of years with recorded NSAID purchases. To estimate the role of yearly amount of NSAID use, the users were stratified to those who used less than 100 DDDs/year and men who used 100 DDD/year or more. Like status on NSAID usage, these variables were updated separately for each year of follow-up according to medication purchases.
Additionally, 1-year and 3-year lag time analyses were performed to evaluate NSAIDs' long-term effects on BPH risk. In this analysis, NSAID exposure was lagged forward in the follow-up time, for example in a 3-year lag time analysis exposure in 1996 would affect the outcome on 1999.
The analyses were carried out using IBM SPSS Statistics 23 statistical software (Chicago, IL).
3 | RESULTS
| Population characteristics
Of the 74 754 participants, 77.2% were NSAID users ( Table 1 ). The median age at baseline was 59 years in both NSAID users and nonusers. The use of antidiabetic drugs, antihypertensive drugs and statins was more common among NSAID users.
| BPH risk by NSAID usage
The risks for BPH-related hospital visits, starting BPH-medication, and BPH surgery were elevated among NSAID users compared to non-users in multivariable-adjusted analyses both for over-thecounter and prescription usage ( Table 2 ). The largest risk increase was observed for usage of BPH drugs, but also the risk of BPH surgery was increased compared to non-users. For prescription use, the risk was highest among men on NSAIDs, whereas in men who discontinued NSAIDs usage the risk elevation was reduced, but remained elevated compared to the non-users. The association was amplified with increasing years of NSAID usage. No clear risk trends were observed by annual amount of NSAID doses; the risk for each BPH endpoint was elevated in both men who had used less than 100
DDDs/year (85% of users) and men who had used 100 DDDs/year or more (15% of users). For BPH diagnosis and BPH surgery the risk elevations were slightly higher among those who used less than 100
DDDs/year.
| BPH risk by use of aspirin and coxibs
Similar to NSAID usage, the use of coxibs was associated with a higher risk of each BPH endpoint ( 
| Lag time analyses
The association between NSAIDs and BPH risk was weaker in both 1-and 3-year lag time analyses compared to the main analysis, but still remained statistically significant (Table 4) . 
| Subgroup analyses
Age, BMI, or antidiabetic drug use did not modify the association between ever-use of NSAIDs and risk of BPH surgery (Fig. 1) . The risk was modified, however, by use of statins and antihypertensive drugs (P for interaction 0.045 and 0.001, respectively); the risk elevation was not as strong among men who had also used these drug groups. Metabolic syndrome has been linked to systemic inflammation, 16 which may also increase the BPH risk. 5 Concordantly, the risk association was modified by background use of cholesterol-lowering and antidiabetic drugs, suggesting that these conditions may have a role in the risk association.
| Sensitivity analyses
Our result differs from secondary analyses of previously published randomized controlled trials, which reported no association with BPH risk. Contrary to this study, randomized trials often use highly selected study populations, which may lead to poor generalizability. Our study population was a population-based cohort with minimal exclusions due to background variables apart from having BPH at baseline. This is probably why the results of this study differ from those of previous randomized trials. This study shows that NSAID use does not decrease the number of clinical BPH diagnoses nor surgical treatment for the condition at the population level.
The findings of this study differ from some previous epidemiological studies. A population-based cohort study of 2447 men reported that daily use of NSAIDs was associated with improved urinary symptoms, increased urine flow rate, and decreased prostate volume and prostate-specific antigen levels, ie, indications of decreased prostatic volume. 10 In contrast to our study, NSAID use in that study was ascertained by a structured interview at baseline and by a questionnaire during the follow-up, meaning that possible changes in NSAID use over time were not thoroughly examined. Additionally, definition for BPH was somewhat different. In addition to BPH treatment (surgery or BPH medications), acute urinary retention, moderate/severe urinary symptoms (as assessed by the AUASI), time to low maximum urinary flow rate (<12 mL/s), prostate volume >30 mL, and serum PSA level >1.4 ng/mL were examined as endpoints.
In another cohort study of 4964 men NSAIDs were not associated with the BPH risk. 12 The main difference between that and our study is the size of the study population. Also, the data on current NSAID use were collected by interviewing the participants at baseline and at each follow-up contact, and BPH was defined as either surgery, medical treatment or sustained, clinically significant BPH symptoms. Only the initiation of NSAID use was taken into consideration, therefore the continuation was assumed. Also the information on dose was not captured. Another difference between our study and these two previous studies is the source of information on NSAID exposure; information collected through surveys likely catches over-the-counter usage for mild and transient need, whereas our study mainly included prescription usage. Thus in our study NSAID users likely had a condition for which prescription use was needed, and as a result the NSAID users as a group could differ between our study and the previous studies.
Similar to our study, another study with a large study population, 34 694 participants, reported a modest excess risk for BPH among NSAID users. 9 In that study, the information on BPH was obtained by questionnaires where history of BPH (enlarged prostate or BPH told by a physician) or surgical treatment (TURP) was asked. The same questionnaires included the information on NSAID use, defined as regular use of aspirin or ibuprofen in last year.
Our study has several strengths. A principal strength is the extensive and detailed data on prescribed NSAID use, as well as several information sources on BPH diagnoses and treatments. These made it possible to assess BPH on multiple levels, from medical treatment to surgery. In addition, the large study population and the long follow-up time increase the validity of this study.
The limited information on the over-the-counter use of NSAIDs is one the limitations. It is more than likely that some men who did not have NSAID prescriptions nevertheless had overthe-counter usage, causing exposure misclassification diluting the observed risk differences. Furthermore, detailed information on indications for NSAID use was not available, along with the knowledge of whether prescribed drugs were actually taken. Our information on BPH came from national health care registers, and the BPH cases in our study population represent men whose condition was severe enough to warrant medication use, health care contact, or surgical treatment. We could not evaluate milder or non-symptomatic forms of BPH.
| CONCLUSIONS
The use of NSAIDs does not lower the risk of BPH at population level.
On the contrary, the risk is higher compared to NSAID non-users.
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